In the last century, vaccines have significantly reduced and even eradicated historically pervasive pathogens. However, rapidly mutating or naturally polymorphic pathogens of HIV, influenza, Chagas disease, sleeping sickness, Dengue and Zika continue to pose challenges to vaccine science. Our patented breakthrough epitope focusing technology, Centivax, focuses the immune response against conserved parts of pathogens that cannot mutate, enabling Universal Vaccine design.


In two repeat studies in sus scrofa (pig) in our animal facility, the epitope focusing vaccine induced antibodies against 39 viral strains of influenza spanning the last century, including all pandemic events (1918 H1N1  Spanish flu, 1957 H2N2 Asian flu, 1968 H3N2 Hong Kong flu, 1977 H1N1  Russian flu, 2002 H3N2 Fujian flu, and 2009 H1N1 Swine flu).


In a Centivax vaccine designed using only pre-2009 viral strain information, the vaccine further elicited broad neutralizing immunity against future pandemic and seasonal viral strains. Observation of an inverse-dose response, single antigen tests, and 159 monoclonal pig antibodies recovered from immunized animals further clarify the mechanism of epitope focusing by Centivax. As our influenza program works towards being applied to the $165M animal market and $3.2B human market, we also expand studies into other critical unmet needs, such as flaviviruses and HIV.

Visit centivax.com to learn more.

Like many other viruses, Influenza has an "Achilles Heel"

Analysis of 6500 different influenza strains highlights a broadly-neutralizing stem epitope of hem agglutinin that cannot mutate and thus is a conserved vaccine target across strains

 (red: conserved, black: often mutated).

(415) 489-0246

201 Gateway Blvd, Floor 1

 South San Francisco, CA 94080, USA